NEW YORK and SHANGHAI, June 22,
2020 /PRNewswire/ -- Cellular Biomedicine Group Inc.
(NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm
engaged in the drug development of immunotherapies for cancer and
stem cell therapies for degenerative diseases, today presented a
poster during the 2020 American Association for Cancer Research
(AACR) annual meeting to be held as a virtual meeting from
June 22-24, 2020.
Poster
Title:
|
"Selecting
Clinical Lead of TCRs Targeting Alpha-Fetoprotein-Positive Liver
Cancer on Balance of Risk and Benefit"
|
Session:
|
Session PO.IM02.04 -
Adoptive Cell Therapy 5
|
Poster
No:
|
6589 (Board
1)
|
Authors:
|
Cellular Biomedicine
Group, Inc, Gaithersburg, MD;
|
|
Georgia Cancer
Center, Augusta University, Augusta, GA
|
Date:
|
Monday, June
22, 2020
|
Time:
|
9:00 a.m.to 6:00 p.m.
EDT
|
Location:
|
San Diego Convention
Center, Exhibit Halls A-F, Poster Virtual Meeting II:
|
|
E-Posters
|
Website:
|
https://www.abstractsonline.com/pp8/#!/9045/presentation/7124
|
C-TCR055 is CBMG's proprietary clinical lead of TCR-T which
specifically recognizes the HLA-A*02:01 restricted
AFP158-166 peptide that is highly expressed in
hepatocellular carcinoma (HCC) and other solid tumors. Preclinical
studies suggested that C-TCR055 has optimal anti-tumor activities
and a good safety profile. CBMG is currently conducting a Phase I
clinical study in unresectable HCC in Fudan University Affiliated
ZhongShang Hospital in Shanghai,
China (NCT03971747).
ABSTRACT
Background: Hepatocellular carcinoma (HCC) is the
most common type of primary liver cancer with a poor prognosis and
limited therapeutic options. Alpha-fetoprotein (AFP), an
established clinical biomarker of HCC, has been employed as an
attractive target for T cell-based immunotherapy against this
disease given its high expression in the tumor and restricted
expression in normal tissues. We have identified a number of T cell
receptors (TCRs) recognizing the HLA-A*02:01 restricted
AFP158-166 peptide FMNKFIYEI, providing a TCR
candidate pool for identifying TCRs with optimal clinical
benefit.
Methods: To select the ideal AFP TCR for clinical
use, we evaluated the efficacy and safety profile of 7 TCRs on
balance of their potency and specificity by testing their
reactivity to normal and transformed cells covering a variety of
primary cell types and HLA serotypes, and potential protein
candidate in human genome by an extensive alanine scan
(X-scan).
Results: We first selected three TCR candidates
based on the in vitro anti-tumor activity. Next we
eliminated two potential cross-reactive TCRs based on their
reactivity against normal and transformed cells covering a variety
of primary cell types and HLA serotypes, respectively. We then
excluded the potential cross-reactivity of the selected TCR with
protein candidates in human genome identified by X-scan.
Conclusion: To date we have selected an AFP TCR
with the optimal affinity, function, and safety profile, bearing
properties that are expected to allow AFP TCR redirected T cells to
specifically differentiate between AFP levels on tumor and normal
tissues. An early phase clinical trial using T cells transduced
with this TCR to treat HCC patients (NCT03971747) has been
initiated.
About Cellular Biomedicine Group, Inc.
Cellular
Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell
therapies for the treatment of cancer and degenerative diseases.
The company conducts immuno-oncology and stem cell clinical trials
in China using products from its
integrated GMP laboratory. The Company's GMP facilities in
China, consisting of twelve
independent cell production lines, are designed and managed
according to both China and U.S.
GMP standards. Its Shanghai
facility includes a "Joint Laboratory of Cell Therapy" with GE
Healthcare and a "Joint Cell Therapy Technology Innovation and
Application Center" with Thermo Fisher Scientific. These
partnerships focus on improving manufacturing processes for cell
therapies. CBMG currently has ongoing CAR-T Phase I clinical trials
in China. The China NMPA (formerly
CFDA) approved the Company's IND application for a Phase II trial
for AlloJoin®, CBMG's "Off-the-Shelf" allogenic haMPC therapy for
the treatment of Knee Osteoarthritis (KOA), and has accepted the
Company's IND application for a Phase II trial for ReJoin®
autologous haMPC therapy for the treatment of KOA. The NMPA has
also accepted CBMG's dossier for an IND application for clinical
trials of anti-BCMA CAR-T. CBMG is included in the broad-market
Russell 3000® Index the small-cap Russell 2000® Index and the
Loncar China BioPharma index. To learn more about CBMG, please
visit www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press
release relating to plans, strategies, specific activities, and
other statements that are not descriptions of historical facts may
be forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include any risks
detailed from time to time in CBMG's reports filed with the
Securities and Exchange Commission, Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K,
including risks relating to the impact of the COVID-19 pandemic on
our operations, including risks associated with the evolving
COVID-19 pandemic and actions taken in response to it. Generally,
the words "believes," "anticipates," "may," "will," "should,"
"could," "expect," "plans," "intend," "estimate," "projects,"
"presents," "potential," "continue" and similar expressions or the
negative thereof or comparable terminology are intended to identify
forward-looking statements. These statements reflect our current
views with respect to future events or to our future
activities and involve known and unknown risks, uncertainties and
other factors which may cause our actual activities, actions or
achievements to be materially different from any future activities,
actions or achievements expressed or implied by the forward-looking
statements. Given these uncertainties, you should not place undue
reliance on these forward-looking statements.
Company Contact:
Derrick C.
Li
Head of Strategy and Investor Relations, CBMG
Phone: 917-717-0994
Email: derrick.li@cellbiomedgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cellular-biomedicine-group-cbmg-presents-poster-of-tcrs-targeting-afp-positive-liver-cancer-at-aacr-annual-meeting-301081019.html
SOURCE Cellular Biomedicine Group